{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:04:25Z","timestamp":1792789465563,"version":"4.5.0"},"reference-count":132,"publisher":"European Respiratory Society (ERS)","issue":"166","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2022,7,27]]},"published-print":{"date-parts":[[2022,12,31]]},"abstract":"<jats:p>Lower respiratory tract infections lead to significant morbidity and mortality. They are increasingly caused by multidrug-resistant pathogens, notably in individuals with cystic fibrosis, hospital-acquired pneumonia and lung transplantation. The use of bacteriophages (phages) to treat bacterial infections is gaining growing attention, with numerous published cases of compassionate treatment over the last few years. Although the use of phages appears safe, the lack of standardisation, the significant heterogeneity of published studies and the paucity of robust efficacy data, alongside regulatory hurdles arising from the existing pharmaceutical legislation, are just some of the challenges phage therapy has to overcome. In this review, we discuss the lessons learned from recent clinical experiences of phage therapy for the treatment of pulmonary infections. We review the key aspects, opportunities and challenges of phage therapy regarding formulations and administration routes, interactions with antibiotics and the immune system, and phage resistance. Building upon the current knowledge base, future pre-clinical studies using emerging technologies and carefully designed clinical trials are expected to enhance our understanding and explore the therapeutic potential of phage therapy.<\/jats:p>","DOI":"10.1183\/16000617.0121-2022","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T04:20:17Z","timestamp":1664943617000},"page":"220121","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations"],"prefix":"10.1183","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-2467","authenticated-orcid":false,"given":"Georgia","family":"Mitropoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Koutsokera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-082X","authenticated-orcid":false,"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-9705","authenticated-orcid":false,"given":"Sylvain","family":"Blanchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Sauty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"von Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-4591","authenticated-orcid":false,"given":"Gr\u00e9gory","family":"Resch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Guery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"2024102404082431000_31.166.220121.1","unstructured":"World Health Organization , The top 10 causes of death. www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Date last updated: 9 December 2020."},{"key":"2024102404082431000_31.166.220121.2","doi-asserted-by":"publisher","DOI":"10.1038\/ismej.2017.16"},{"key":"2024102404082431000_31.166.220121.3","doi-asserted-by":"publisher","DOI":"10.4161\/bact.1.1.14942"},{"key":"2024102404082431000_31.166.220121.4","doi-asserted-by":"publisher","DOI":"10.1080\/21597081.2015.1020260"},{"key":"2024102404082431000_31.166.220121.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30482-1"},{"key":"2024102404082431000_31.166.220121.6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","article-title":"Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomised trial in children from Bangladesh","volume":"4","author":"Sarker","year":"2016","journal-title":"EBioMedicine"},{"key":"2024102404082431000_31.166.220121.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01973.x"},{"key":"2024102404082431000_31.166.220121.8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(20)30330-3","article-title":"Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial","volume":"21","author":"Leitner","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024102404082431000_31.166.220121.9","unstructured":"ClinicalTrials.gov . Bacteriophage therapy in patients with urinary tract infections. NCT04287478. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04287478 Date last accessed: 27 June 2022. Date last updated: 7 December 2021."},{"key":"2024102404082431000_31.166.220121.10","unstructured":"ClinicalTrials.gov . Ph 1\/2 study evaluating safety and tolerability of inhaled AP-PA02 in subjects with chronic Pseudomonas aeruginosa lung infections and cystic fibrosis (SWARM-Pa). NCT04596319. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04596319 Date last accessed: 27 June 2022. Date last updated: 29 November 2021."},{"key":"2024102404082431000_31.166.220121.11","unstructured":"ClinicalTrials.gov . Bacteriophage therapy in patients with diabetic foot osteomyelitis. NCT05177107. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05177107 Date last accessed: 27 June 2022. Date last updated: 1 August 2022."},{"key":"2024102404082431000_31.166.220121.12","unstructured":"ClinicalTrials.gov . Bacteriophage therapy TP-102 in diabetic foot ulcers (REVERSE). NCT04803708. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04803708 Date last accessed: 27 June 2022. Date last updated: 21 June 2022."},{"key":"2024102404082431000_31.166.220121.13","unstructured":"ClinicalTrials.gov . Study evaluating safety, tolerability, and efficacy of intravenous AP-SA02 in subjects with S. Aureus bacteremia (diSArm). NCT05184764. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05184764 Date last accessed: 27 June 2022. Date last updated: 17 May 2022."},{"key":"2024102404082431000_31.166.220121.14","unstructured":"ClinicalTrials.gov . CYstic fibrosis bacterioPHage study at Yale (CYPHY). NCT04684641. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04684641;. Date last accessed: 27 June 2022. Date last updated: 8 October 2021."},{"key":"2024102404082431000_31.166.220121.15","unstructured":"ClinicalTrials.gov . Nebulized bacteriophage therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection. NCT05010577. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05010577 Date late accessed: 27 June 2022. Date last updated: 30 June 2022."},{"key":"2024102404082431000_31.166.220121.16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1164\/rccm.201904-0839LE","article-title":"Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa","volume":"200","author":"Maddocks","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404082431000_31.166.220121.17","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-019-01319-0"},{"key":"2024102404082431000_31.166.220121.18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.resmic.2018.05.001","article-title":"Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report","volume":"169","author":"Hoyle","year":"2018","journal-title":"Res Microbiol"},{"key":"2024102404082431000_31.166.220121.19","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient","volume":"55","author":"Gainey","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2024102404082431000_31.166.220121.20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/v13010060","article-title":"A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient","volume":"13","author":"Lebeaux","year":"2021","journal-title":"Viruses"},{"key":"2024102404082431000_31.166.220121.21","doi-asserted-by":"crossref","first-page":"AAC0082421","DOI":"10.1128\/AAC.00824-21","article-title":"Critically ill patient with multidrug-resistant Acinetobacter baumannii respiratory infection successfully treated with intravenous and nebulized bacteriophage therapy","volume":"66","author":"Rao","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102404082431000_31.166.220121.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0437-z"},{"key":"2024102404082431000_31.166.220121.23","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","article-title":"Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection","volume":"27","author":"Dedrick","year":"2021","journal-title":"Nat Med"},{"key":"2024102404082431000_31.166.220121.24","doi-asserted-by":"crossref","first-page":"631585","DOI":"10.3389\/fcimb.2021.631585","article-title":"Clinical experience of personalized phage therapy against carbapenem-resistant Acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease","volume":"11","author":"Tan","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2024102404082431000_31.166.220121.25","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","article-title":"Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection","volume":"185","author":"Nick","year":"2022","journal-title":"Cell"},{"key":"2024102404082431000_31.166.220121.26","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15503"},{"key":"2024102404082431000_31.166.220121.27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/antibiotics9050232","article-title":"Bacteriophage therapy for critical infections related to cardiothoracic surgery","volume":"9","author":"Rubalskii","year":"2020","journal-title":"Antibiotics"},{"key":"2024102404082431000_31.166.220121.28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/22221751.2021.1902754","article-title":"Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients","volume":"10","author":"Wu","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"2024102404082431000_31.166.220121.29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","article-title":"Safety of bacteriophage therapy in severe Staphylococcus aureus infection","volume":"5","author":"Petrovic Fabijan","year":"2020","journal-title":"Nat Microbiol"},{"key":"2024102404082431000_31.166.220121.30","doi-asserted-by":"publisher","DOI":"10.3390\/v10040178"},{"key":"2024102404082431000_31.166.220121.31","unstructured":"World Medical Association . WMA declaration of Helsinki \u2013 ethical principles for medical research involving human subjects. www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects Date last updated: 9 July 2018."},{"key":"2024102404082431000_31.166.220121.32","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/cid\/ciz782","article-title":"Eradication of a multidrug-resistant, carbapenemase-producing Klebsiella pneumoniae isolate following oral and intra-rectal therapy with a custom made, lytic bacteriophage preparation","volume":"70","author":"Corbellino","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024102404082431000_31.166.220121.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024102404082431000_31.166.220121.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024102404082431000_31.166.220121.35","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807120"},{"key":"2024102404082431000_31.166.220121.36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404082431000_31.166.220121.37","doi-asserted-by":"crossref","unstructured":"Liu D , Van Belleghem JD , de Vries CR , et al. The safety and toxicity of phage therapy: a review of animal and clinical studies. Viruses 2021; 13: 1268. doi:10.3390\/v13071268","DOI":"10.3390\/v13071268"},{"key":"2024102404082431000_31.166.220121.38","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","article-title":"Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review","volume":"22","author":"Uyttebroek","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024102404082431000_31.166.220121.39","unstructured":"US Food and Drug Administration . Bacterial endotoxins\/pyrogens. https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/inspection-technical-guides\/bacterial-endotoxinspyrogens Date last updated: 17 November 2014."},{"key":"2024102404082431000_31.166.220121.40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40168-021-01026-9","article-title":"Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection","volume":"9","author":"Mu","year":"2021","journal-title":"Microbiome"},{"key":"2024102404082431000_31.166.220121.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.05.001"},{"key":"2024102404082431000_31.166.220121.42","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02287-16"},{"key":"2024102404082431000_31.166.220121.43","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021115-105238"},{"key":"2024102404082431000_31.166.220121.44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ccm.2015.10.003","article-title":"The microbiome in cystic fibrosis","volume":"37","author":"Huang","year":"2016","journal-title":"Clin Chest Med"},{"key":"2024102404082431000_31.166.220121.45","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-021-22344-4","article-title":"A prevalent and culturable microbiota links ecological balance to clinical stability of the human lung after transplantation","volume":"12","author":"Das","year":"2021","journal-title":"Nat Commun"},{"key":"2024102404082431000_31.166.220121.46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41423-020-00532-4","article-title":"Phages and their potential to modulate the microbiome and immunity","volume":"18","author":"Federici","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2024102404082431000_31.166.220121.47","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.athoracsur.2019.12.075","article-title":"Outcomes of adult patients with septic shock undergoing extracorporeal membrane oxygenation therapy","volume":"110","author":"Myers","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"2024102404082431000_31.166.220121.48","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200503-344OC"},{"key":"2024102404082431000_31.166.220121.49","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro822"},{"key":"2024102404082431000_31.166.220121.50","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.25190","article-title":"Bacteriophage therapy for infections in CF","volume":"56","author":"Chan","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2024102404082431000_31.166.220121.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08336-9"},{"key":"2024102404082431000_31.166.220121.52","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.3389\/fimmu.2019.02607","article-title":"Induction of phage-specific antibodies by two therapeutic staphylococcal bacteriophages administered per os","volume":"10","author":"Majewska","year":"2019","journal-title":"Front Immunol"},{"key":"2024102404082431000_31.166.220121.53","doi-asserted-by":"crossref","first-page":"639570","DOI":"10.3389\/fimmu.2021.639570","article-title":"Immune response to therapeutic staphylococcal bacteriophages in mammals: kinetics of induction, immunogenic structural proteins, natural and induced antibodies","volume":"12","author":"Kazmierczak","year":"2021","journal-title":"Front Immunol"},{"key":"2024102404082431000_31.166.220121.54","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1038\/s41467-022-29689-4","article-title":"Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection","volume":"13","author":"Little","year":"2022","journal-title":"Nat Commun"},{"key":"2024102404082431000_31.166.220121.55","doi-asserted-by":"publisher","DOI":"10.3390\/v11010010"},{"key":"2024102404082431000_31.166.220121.56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.21775\/cimb.040.081","article-title":"Phage therapy: the pharmacology of antibacterial viruses","volume":"40","author":"Danis-Wlodarczyk","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"2024102404082431000_31.166.220121.57","doi-asserted-by":"crossref","first-page":"e01714","DOI":"10.1128\/AAC.01714-17","article-title":"Proof-of-principle study in a murine lung infection model of antipseudomonal activity of phage PEV20 in a dry-powder formulation","volume":"62","author":"Chang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102404082431000_31.166.220121.58","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejpb.2020.11.019","article-title":"Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-a proof-of-principle study in a P. aeruginosa lung infection model","volume":"158","author":"Lin","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"2024102404082431000_31.166.220121.59","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cmi.2022.01.006","article-title":"The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice","volume":"28","author":"Chang","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024102404082431000_31.166.220121.60","doi-asserted-by":"publisher","DOI":"10.1007\/s12275-011-1512-4"},{"key":"2024102404082431000_31.166.220121.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2017.06.018"},{"key":"2024102404082431000_31.166.220121.62","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2013.0128"},{"key":"2024102404082431000_31.166.220121.63","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/antibiotics10060627","article-title":"Low immunogenicity of intravesical phage therapy for urogenitary tract infections","volume":"10","author":"Letkiewicz","year":"2021","journal-title":"Antibiotics"},{"key":"2024102404082431000_31.166.220121.64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s13337-021-00673-8","article-title":"Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model","volume":"32","author":"Archana","year":"2021","journal-title":"Virusdisease"},{"key":"2024102404082431000_31.166.220121.65","first-page":"553","article-title":"Immunogenic effect of bacteriophage in patients subjected to phage therapy","volume":"35","author":"Kucharewicz-Krukowska","year":"1987","journal-title":"Arch Immunol Ther Exp"},{"key":"2024102404082431000_31.166.220121.66","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02043-14"},{"key":"2024102404082431000_31.166.220121.67","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01681"},{"key":"2024102404082431000_31.166.220121.68","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/v13061182","article-title":"Successful treatment of Staphylococcus aureus prosthetic joint infection with bacteriophage therapy","volume":"13","author":"Ramirez-Sanchez","year":"2021","journal-title":"Viruses"},{"key":"2024102404082431000_31.166.220121.69","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa389"},{"key":"2024102404082431000_31.166.220121.70","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03441-20"},{"key":"2024102404082431000_31.166.220121.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.07.036"},{"key":"2024102404082431000_31.166.220121.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.femsre.2003.08.001"},{"key":"2024102404082431000_31.166.220121.73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/IDR.S234353","article-title":"How phages overcome the challenges of drug resistant bacteria in clinical infections","volume":"13","author":"Moghadam","year":"2020","journal-title":"Infect Drug Resist"},{"key":"2024102404082431000_31.166.220121.74","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1007\/s00284-021-02662-y","article-title":"Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant Gram-negative bacteria","volume":"78","author":"Mousavi","year":"2021","journal-title":"Curr Microbiol"},{"key":"2024102404082431000_31.166.220121.75","unstructured":"World Health Organization . 2020 Antibacterial Agents in Clinical and Preclinical Development: an Overview and Analysis. Geneva, World Health Organization, 2021."},{"key":"2024102404082431000_31.166.220121.76","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00954-17"},{"key":"2024102404082431000_31.166.220121.77","doi-asserted-by":"publisher","DOI":"10.1093\/emph\/eoy005"},{"key":"2024102404082431000_31.166.220121.78","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01281-19"},{"key":"2024102404082431000_31.166.220121.79","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/22221751.2020.1747950","article-title":"Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae","volume":"9","author":"Bao","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2024102404082431000_31.166.220121.80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000799"},{"key":"2024102404082431000_31.166.220121.81","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02850-14"},{"key":"2024102404082431000_31.166.220121.82","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-018-3811-0"},{"key":"2024102404082431000_31.166.220121.83","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02085-18"},{"key":"2024102404082431000_31.166.220121.84","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3389\/fmicb.2020.01947","article-title":"Combined bacteriophage and antibiotic treatment prevents Pseudomonas aeruginosa infection of wild type and cftr- epithelial cells","volume":"11","author":"Luscher","year":"2020","journal-title":"Front Microbiol"},{"key":"2024102404082431000_31.166.220121.85","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.K.01135"},{"key":"2024102404082431000_31.166.220121.86","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02877-15"},{"key":"2024102404082431000_31.166.220121.87","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fcimb.2019.00022","article-title":"Fighting pathogenic bacteria on two fronts: phages and antibiotics as combined strategy","volume":"9","author":"Tagliaferri","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"2024102404082431000_31.166.220121.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.09.024"},{"key":"2024102404082431000_31.166.220121.89","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2016.94"},{"key":"2024102404082431000_31.166.220121.90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2672.2009.04469.x"},{"key":"2024102404082431000_31.166.220121.91","doi-asserted-by":"crossref","first-page":"104834","DOI":"10.1093\/femspd\/ftz011","article-title":"P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination","volume":"77","author":"Henriksen","year":"2019","journal-title":"Pathog Dis"},{"key":"2024102404082431000_31.166.220121.92","doi-asserted-by":"crossref","first-page":"ftz011","DOI":"10.1016\/j.micpath.2021.104834","article-title":"Expression of virulence factors by Pseudomonas aeruginosa biofilm after bacteriophage infection","volume":"154","author":"Oliveira","year":"2021","journal-title":"Microb Pathog"},{"key":"2024102404082431000_31.166.220121.93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168615"},{"key":"2024102404082431000_31.166.220121.94","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1208\/s12248-019-0315-0","article-title":"Bacteriophage PEV20 and ciprofloxacin combination treatment enhances removal of Pseudomonas aeruginosa biofilm isolated from cystic fibrosis and wound patients","volume":"21","author":"Chang","year":"2019","journal-title":"AAPS J"},{"key":"2024102404082431000_31.166.220121.95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.09.006"},{"key":"2024102404082431000_31.166.220121.96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77198-5"},{"key":"2024102404082431000_31.166.220121.97","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00127"},{"key":"2024102404082431000_31.166.220121.98","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13104-021-05796-1","article-title":"Searching for synergy: combining systemic daptomycin treatment with localised phage therapy for the treatment of experimental pneumonia due to MRSA","volume":"14","author":"Valente","year":"2021","journal-title":"BMC Res Notes"},{"key":"2024102404082431000_31.166.220121.99","doi-asserted-by":"crossref","first-page":"e0207121","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102404082431000_31.166.220121.100","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2015.1233"},{"key":"2024102404082431000_31.166.220121.101","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00012-19"},{"key":"2024102404082431000_31.166.220121.102","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/infdis\/jiab112","article-title":"Benefits of aerosolized phages for the treatment of pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA): an experimental study in rats","volume":"225","author":"Prazak","year":"2021","journal-title":"J Infect Dis"},{"key":"2024102404082431000_31.166.220121.103","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1164\/rccm.201812-2372OC","article-title":"Bacteriophages improve outcomes in experimental Staphylococcus aureus ventilator-associated pneumonia","volume":"200","author":"Prazak","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404082431000_31.166.220121.104","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy064"},{"key":"2024102404082431000_31.166.220121.105","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01470-20"},{"key":"2024102404082431000_31.166.220121.106","doi-asserted-by":"crossref","first-page":"120200","DOI":"10.1016\/j.ijpharm.2021.120200","article-title":"Phage cocktail powder for Pseudomonas aeruginosa respiratory infections","volume":"596","author":"Li","year":"2021","journal-title":"Int J Pharm"},{"key":"2024102404082431000_31.166.220121.107","doi-asserted-by":"crossref","first-page":"758392","DOI":"10.3389\/fcimb.2021.758392","article-title":"Prospects of inhaled phage therapy for combatting pulmonary infections","volume":"11","author":"Wang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2024102404082431000_31.166.220121.108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.11.026"},{"key":"2024102404082431000_31.166.220121.109","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2213-4"},{"key":"2024102404082431000_31.166.220121.110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.21775\/cimb.040.303","article-title":"Bacteriophage encapsulation using spray drying for phage therapy","volume":"40","author":"Malik","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"2024102404082431000_31.166.220121.111","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-164-6_14"},{"key":"2024102404082431000_31.166.220121.112","doi-asserted-by":"crossref","first-page":"e0216292","DOI":"10.1371\/journal.pone.0216292","article-title":"Fast phage detection and quantification: an optical density-based approach","volume":"14","author":"Rajnovic","year":"2019","journal-title":"PLoS One"},{"key":"2024102404082431000_31.166.220121.113","doi-asserted-by":"publisher","DOI":"10.1038\/srep26717"},{"key":"2024102404082431000_31.166.220121.114","doi-asserted-by":"crossref","first-page":"fuab040","DOI":"10.1093\/femsre\/fuab040","article-title":"Recent progress towards the implementation of phage therapy in Western medicine","volume":"46","author":"Pirnay","year":"2021","journal-title":"FEMS Microbiol Rev"},{"key":"2024102404082431000_31.166.220121.115","doi-asserted-by":"crossref","first-page":"638094","DOI":"10.3389\/fmicb.2021.638094","article-title":"Potential of therapeutic bacteriophages in nosocomial infection management","volume":"12","author":"Wu","year":"2021","journal-title":"Front Microbiol"},{"key":"2024102404082431000_31.166.220121.116","unstructured":"European Commission . EudraLex \u2013 Volume 4 \u2013 Good Manufacturing Practice (GMP) guidelines. https:\/\/health.ec.europa.eu\/medicinal-products\/eudralex\/eudralex-volume-4_en"},{"key":"2024102404082431000_31.166.220121.117","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.19.100165.002053"},{"key":"2024102404082431000_31.166.220121.118","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00580-17"},{"key":"2024102404082431000_31.166.220121.119","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201489455"},{"key":"2024102404082431000_31.166.220121.120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41564-017-0051-0","article-title":"DISARM is a widespread bacterial defence system with broad anti-phage activities","volume":"3","author":"Ofir","year":"2018","journal-title":"Nat Microbiol"},{"key":"2024102404082431000_31.166.220121.121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005282"},{"key":"2024102404082431000_31.166.220121.122","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/nar\/gkaa290","article-title":"Phage T7 DNA mimic protein Ocr is a potent inhibitor of BREX defence","volume":"48","author":"Isaev","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2024102404082431000_31.166.220121.123","doi-asserted-by":"crossref","first-page":"e73679","DOI":"10.7554\/eLife.73679","article-title":"Parallel evolution of Pseudomonas aeruginosa phage resistance and virulence loss in response to phage treatment in vivo and in vitro","volume":"11","author":"Castledine","year":"2022","journal-title":"Elife"},{"key":"2024102404082431000_31.166.220121.124","doi-asserted-by":"publisher","DOI":"10.3390\/v10060323"},{"key":"2024102404082431000_31.166.220121.125","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw632"},{"key":"2024102404082431000_31.166.220121.126","doi-asserted-by":"crossref","first-page":"101201","DOI":"10.1016\/j.coviro.2022.101201","article-title":"Mitigation of evolved bacterial resistance to phage therapy","volume":"53","author":"Torres-Barcelo","year":"2022","journal-title":"Curr Opin Virol"},{"key":"2024102404082431000_31.166.220121.127","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2104592118"},{"key":"2024102404082431000_31.166.220121.128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008032"},{"key":"2024102404082431000_31.166.220121.129","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.3389\/fmicb.2019.02973","article-title":"Overexpression of AmpC promotes bacteriophage lysis of ampicillin-resistant Escherichia coli","volume":"10","author":"Wang","year":"2019","journal-title":"Front Microbiol"},{"key":"2024102404082431000_31.166.220121.130","doi-asserted-by":"crossref","first-page":"783722","DOI":"10.3389\/fmicb.2021.783722","article-title":"Survival comes at a cost: a coevolution of phage and its host leads to phage resistance and antibiotic sensitivity of pseudomonas aeruginosa multidrug resistant strains","volume":"12","author":"Koderi Valappil","year":"2021","journal-title":"Front Microbiol"},{"key":"2024102404082431000_31.166.220121.131","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.molcel.2020.12.011","article-title":"A phage-encoded anti-activator inhibits quorum sensing in Pseudomonas aeruginosa","volume":"81","author":"Shah","year":"2021","journal-title":"Mol Cell"},{"key":"2024102404082431000_31.166.220121.132","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00756-19"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0121-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:05:25Z","timestamp":1740355525000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0121-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":132,"journal-issue":{"issue":"166","published-online":{"date-parts":[[2022,10,5]]},"published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1183\/16000617.0121-2022"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0121-2022","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]}}}